Lifestyle changes for cognition and dementia: better than a new drug?

shutterstock_2378100

Should all molecular research institutes looking at neurodegenerative diseases be replaced by parks, playgrounds and cycle paths? Mark Horowitz highlights a recent systematic review of modifiable risk factors associated with cognition and dementia, which suggests that from a public health perspective, there may be some sense in this idea.

[read the full story...]

Short-term psychodynamic psychotherapy for all common mental health disorders?

shutterstock_171530327

For his ninth Mental Elf blog, Mark Smith reports on a Cochrane systematic review of the effectiveness of short term psychodynamic therapies on common mental health disorders.

[read the full story...]

Collaborative care for depression: psychological interventions, alone or in combination with medication, offer additional benefits

A recent meta-analysis sought to identify factors associated with improvement in patient outcomes and in the process of care

Ioana Cristea reviews a recent systematic review and meta-analysis of collaborative care for depression, looking to identify factors predicting improvements. The study finds that collaborative care successfully improves both patient outcomes and the process of care for depression.

[read the full story...]

Cannabis and mania: what’s the link?

Cannabis

Kathryn Walsh summarises a systematic review which finds that cannabis use may exacerbate symptoms of mania in those with a diagnosis of bipolar disorder, and trigger symptoms of mania in the general population.

[read the full story...]

Long duration of untreated psychosis is associated with a range of poor outcomes

shutterstock_111899612

Joe Judge appraises a recent systematic review and meta-analysis looking at the duration of untreated psychosis as a predictor of long-term outcomes in schizophrenia.

[read the full story...]

Antidepressants for depression in pregnancy: new systematic review says the jury’s still out

Nikki Newhouse summarises a recent US health technology assessment of antidepressants for depression in pregnancy and the postpartum period, which concludes that the evidence remains inconclusive about the benefits and harms of antidepressants for depression in pregnancy.

[read the full story...]

Efficacy of high vs. low-potency first-generation antipsychotics for schizophrenia

Screen Shot 2014-10-03 at 13.24.52

Laurence Palfreyman summarises 3 recent Cochrane reviews, which investigate high-potency versus low-potency first-generation antipsychotic drugs for schizophrenia. The reviews find little difference in efficacy between the high-potency antipsychotics Trifluoperazine, Haloperidol, Fluphenazine, and low-potency typical antipsychotics.

[read the full story...]

Schizophrenia and osteoporosis: sticks and stones may break my bones…

shutterstock_179004116

Chris Pell summarises a recent meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. The study finds a significantly increased risk of osteoporosis in people with schizophrenia.

[read the full story...]

Exercise for the prevention and treatment of antenatal depression

shutterstock_59173807

Meg Fluharty summarises a recent systematic review looking at exercise for antenatal depression. The review finds preliminary evidence to suggest that exercise may be effective in reducing depression during pregnancy, but the quality of included trials is low to moderate.

[read the full story...]